.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Accenture
McKinsey
Daiichi Sankyo
Chubb
Boehringer Ingelheim
Mallinckrodt
Colorcon
Federal Trade Commission
Moodys

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090529

« Back to Dashboard

NDA 090529 describes VERAPAMIL HYDROCHLORIDE, which is a drug marketed by Mylan, Abraxis Pharm, Bedford, Hospira, Intl Medication, Luitpold, Marsam Pharms Llc, Smith And Nephew, Solopak, Exela Pharma Scs Llc, Apotex Corp, Cadila Pharms Ltd, Glenmark Generics, Ivax Sub Teva Pharms, Par Pharm, Pliva, Sun Pharm Inds Inc, Actavis Elizabeth, Heritage Pharms Inc, Mutual Pharm, Sandoz, Sun Pharm Industries, Warner Chilcott, and Watson Labs, and is included in fifty-four NDAs. It is available from thirty-seven suppliers. Additional details are available on the VERAPAMIL HYDROCHLORIDE profile page.

The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are sixteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

Summary for 090529

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 090529

Suppliers and Packaging for NDA: 090529

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 090529 ANDA PD-Rx Pharmaceuticals, Inc. 43063-561 43063-561-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (43063-561-30)
VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 090529 ANDA PD-Rx Pharmaceuticals, Inc. 43063-562 43063-562-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (43063-562-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength120MG
Approval Date:Dec 30, 2011TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength180MG
Approval Date:Dec 30, 2011TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength240MG
Approval Date:Dec 30, 2011TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Express Scripts
US Army
Novartis
Deloitte
UBS
Citi
Merck
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot